This study presents valuable findings implicating nuclear export in the regulation of protein condensate behaviour and TDP-43 phase behaviour, suggesting a link to pathogenic aggregation in ALS/FTD.
For the first half of FY2024-25, the company's PAT increased to ₹63.07 crore, compared to ₹59.62 crore during the same period in the previous fiscal year.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results